Acceleron Pharma

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q3 2019 Results - Earnings Call Transcript

The biotech's Q3 results and future fortunes hinge on approvals for the blood-disease drug it licensed to Celgene.

Acceleron's Q3 Results Focus Squarely on Its Celgene Collaboration

Acceleron (XLRN) delivered earnings and revenue surprises of -6.17% and 22.11%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Acceleron Pharma (XLRN) Reports Q3 Loss, Tops Revenue Estimates

The biotech’s pipeline is shrinking, but investors should focus on what will drive near-term value.

Here’s Why Acceleron Pharma Stock Fell 12% in September

The small pharma company had disappointing results from its second phase clinical trials. Here’s why it’s too soon to throw in the towel.

Don't Dismiss Acceleron Despite Its Recent Clinical Setback

Shares of Acceleron Pharma Inc. fell nearly 4% in the extended session Monday after the biopharmaceutical company said one of its treatments aimed at a type of muscular dystrophy showed no evidence of benefits relative to a placebo.

Acceleron Pharma stock down 4% after company halts treatment trial

The FDA assigns an orphan drug status to Acceleron's (XLRN) investigational therapy sotatercept for the treatment of patients with pulmonary arterial hypertension. Shares inch up.

FDA Grants Orphan Drug Status to Acceleron's PAH Candidate

Cambridge, Massachusetts-based Acceleron Pharma Inc (NASDAQ: XLRN) said Monday that the FDA has accorded Orphan Drug Designation to its sotatercept.

Acceleron's Pulmonary Arterial Hypertension Asset Receives Orphan Drug Designation

The big story for Acceleron: waiting on good news for luspatercept.

What You'll Want to Know About Acceleron Pharma's Q2 Update

Acceleron Pharma Inc. (XLRN) CEO Habib Dable on Q2 2019 Results - Earnings Call Transcript

Bristol-Myers

Celgene

Johnson & Johnson

Celgene (CELG) along with partner Acceleron submits application for luspatercept to the FDA.

Celgene & Acceleron's BLA for Luspatercept Accepted by FDA

Acceleron Pharma's (XLRN) CEO Habib Dable on Q1 2019 Results - Earnings Call Transcript

Celgene announced that it had submitted its BLA to receive FDA approval for luspatercept to treat patients with two diseases that are associated with anemia.

Celgene And Acceleron: BLA Luspatercept Has Strong Potential

Celgene and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.

News for Acceleron Pharma Stock (XLRN)